Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Bladder Cancer

  Free Subscription


Articles published in BJU Int

Retrieve available abstracts of 115 articles:
HTML format



Single Articles


    June 2020
  1. GAKIS G, Karl A, Bertz S, Burger M, et al
    Transurethral en bloc submucosal hydrodissection versus conventional resection for resection of non-muscle invasive bladder cancer (HYBRIDBLUE): a randomized, multicentre trial.
    BJU Int. 2020 Jun 23. doi: 10.1111/bju.15150.
    PubMed     Abstract available


  2. HENTSCHEL AE, van EE, der Toom, Vis AN, et al
    A Systematic Review on Mutation Markers for Bladder Cancer Diagnosis in Urine.
    BJU Int. 2020 Jun 15. doi: 10.1111/bju.15137.
    PubMed     Abstract available


  3. MCCLOSKEY H, Hamad J, Smith AB
    How can we motivate patients with bladder cancer to help themselves?
    BJU Int. 2020;125:751-752.
    PubMed    


    March 2020
  4. MANNION L, Bosco C, Nair R, Mullassery V, et al
    Overall survival, disease specific survival and local recurrence outcomes in patients with muscle invasive bladder cancer treated with external beam radiotherapy and brachytherapy: A systematic review.
    BJU Int. 2020 Mar 7. doi: 10.1111/bju.15047.
    PubMed     Abstract available


  5. MOSTAFID AH, Porta N, Cresswell J, Griffiths T, et al
    CALIBER - A phase II randomised feasibility trial of chemoablation with mitomycin versus surgical management in low risk non-muscle invasive bladder cancer.
    BJU Int. 2020 Mar 3. doi: 10.1111/bju.15038.
    PubMed     Abstract available


    February 2020
  6. JANISCH F, Rink M, Shariat SF
    The promise and challenges of neoadjuvant immunotherapy in the management of non-metastatic muscle-invasive bladder cancer.
    BJU Int. 2020 Feb 3. doi: 10.1111/bju.15025.
    PubMed     Abstract available


    January 2020
  7. CHUNG J, Maganti M, Kulkarni GS, Morash R, et al
    Modifiable Lifestyle Behaviours Impact the Health-Related Quality of Life of Bladder Cancer Survivors.
    BJU Int. 2020 Jan 24. doi: 10.1111/bju.15007.
    PubMed     Abstract available


  8. TAN WS, Teo CH, Chan D, Ang KM, et al
    Exploring patients' experience and perception of being diagnosed with bladder cancer: A mixed methods approach.
    BJU Int. 2020 Jan 23. doi: 10.1111/bju.15008.
    PubMed     Abstract available


  9. MATULAY JT, Soloway M, Witjes JA, Buckley R, et al
    Risk Adapted Management of Low-Grade Bladder Tumors: Recommendations from the International Bladder Cancer Group.
    BJU Int. 2020 Jan 16. doi: 10.1111/bju.14995.
    PubMed     Abstract available


  10. MOSSANEN M, Chang SL
    Beyond bladder cancer surveillance: building a survivorship clinic.
    BJU Int. 2020;125:2-3.
    PubMed    


    October 2019
  11. TAYLOR J, Becher E, Steinberg GD
    Update on the Guideline of Guidelines: Non-Muscle Invasive Bladder Cancer.
    BJU Int. 2019 Oct 9. doi: 10.1111/bju.14915.
    PubMed     Abstract available


    September 2019
  12. JAIN RK, Grivas P, Pal SK
    Non-invasive diagnosis and monitoring of urothelial bladder cancer: are we there yet?
    BJU Int. 2019;124:361-362.
    PubMed    


    August 2019
  13. JUNG A, Nielsen ME, Crandell JL, Palmer MH, et al
    Health-Related Quality of Life among Non-Muscle-Invasive Bladder Cancer Survivors: A Population-Based Study.
    BJU Int. 2019 Aug 5. doi: 10.1111/bju.14888.
    PubMed     Abstract available


  14. FILIPPOU P, Smith AB
    A new horizon for bladder preservation in muscle-invasive bladder cancer.
    BJU Int. 2019;124:184-185.
    PubMed    


    July 2019
  15. MARTINI A, Sfakianos JP, Renstrom-Koskela L, Mortezavi A, et al
    The Natural History of Untreated Muscle Invasive Bladder Cancer.
    BJU Int. 2019 Jul 16. doi: 10.1111/bju.14872.
    PubMed     Abstract available


  16. RAI BP, Bondad J, Vasdev N, Adshead J, et al
    Robotic versus open radical cystectomy for bladder cancer in adults.
    BJU Int. 2019 Jul 15. doi: 10.1111/bju.14870.
    PubMed     Abstract available


  17. HAMPSON A, Vincent A, Dasgupta P, Vasdev N, et al
    Radical cystectomy complications and perioperative mortality.
    BJU Int. 2019;124:3-4.
    PubMed    


    June 2019
  18. MCCLINTOCK TR
    Palliative care in patients with bladder cancer: an opportunity for value improvement?
    BJU Int. 2019;123:913-914.
    PubMed    


  19. DOYLE E, Crew J, Mostafid H, Tuthill M, et al
    Urothelial cancer: a narrative review of the role of novel immunotherapeutic agents with particular reference to the management of non-muscle-invasive disease.
    BJU Int. 2019;123:947-958.
    PubMed     Abstract available


    May 2019
  20. MAZZONE E, Mistretta FA, Knipper S, Palumbo C, et al
    Long-Term Incidence of Secondary Bladder, Rectal Cancer in Patients Treated with Brachytherapy for Localized Prostate Cancer: A Large-Scale Population-Based Analysis.
    BJU Int. 2019 May 30. doi: 10.1111/bju.14841.
    PubMed     Abstract available


  21. WARD DG, Gordon NS, Boucher RH, Pirrie SJ, et al
    Targeted deep sequencing of urothelial bladder cancers and associated urinary DNA: a 23-gene panel with utility for non-invasive diagnosis and risk stratification.
    BJU Int. 2019 May 11. doi: 10.1111/bju.14808.
    PubMed     Abstract available


  22. YU EY, Nekeman D, Aaronson NK, Billingham LJ, et al
    Health-Related Quality of Life in Bladder Cancer Patients around the Time of Diagnosis.
    BJU Int. 2019 May 11. doi: 10.1111/bju.14804.
    PubMed     Abstract available


  23. SEILER R, Wyatt AW, Black PC
    Molecular landscape of muscle-invasive bladder cancer: Patient age matter?
    BJU Int. 2019 May 9. doi: 10.1111/bju.14802.
    PubMed     Abstract available


  24. MOSSANEN M, Kibel AS
    The bladder cancer conundrum: how do we treat the right tumour with the right treatment, at the right time?
    BJU Int. 2019;123:748-749.
    PubMed    


    March 2019
  25. KHETRAPAL P, Kelly JD, Catto JWF, Vasdev N, et al
    Does the robot have a role in radical cystectomy?
    BJU Int. 2019;123:380-382.
    PubMed    


    February 2019
  26. KIJIMA T, Tanaka H, Koga F, Masuda H, et al
    Selective Tetramodal Bladder Preservation Therapy Incorporating Induction Chemoradiotherapy and Consolidative Partial Cystectomy with Pelvic Lymph Node Dissection for Muscle-Invasive Bladder Cancer: Oncological and Functional Outcomes of 107 Patients.
    BJU Int. 2019 Feb 27. doi: 10.1111/bju.14736.
    PubMed     Abstract available


  27. TARIQ A, Khan SR, Vela I, Williams ED, et al
    Assessment of bladder cancer patients and carers use of internet, social media and quality of available patient centric online resources: A systematic review.
    BJU Int. 2019 Feb 24. doi: 10.1111/bju.14720.
    PubMed     Abstract available


  28. HUGAR LA, Lopa SH, Yabes JG, Yu JA, et al
    Palliative Care Use Among Patients with Bladder Cancer.
    BJU Int. 2019 Feb 13. doi: 10.1111/bju.14708.
    PubMed     Abstract available


  29. DHARIWAL R, Pindoria N, Dasgupta P, Khan MS, et al
    #Checkmate: could checkpoint inhibitors be the game changer in the fight against metastatic urothelial carcinoma?
    BJU Int. 2019;123:203-207.
    PubMed    


  30. NURMINEN P, Ettala O, Seppanen M, Taimen P, et al
    Urine cytology is a feasible tool for assessing erythematous bladder lesions after bacille Calmette-Guerin (BCG) treatment.
    BJU Int. 2019;123:246-251.
    PubMed     Abstract available


  31. KINNEAR N, O'Callaghan M, Hennessey D, Liddell H, et al
    Intra-operative cell salvage in urological surgery: a systematic review and meta-analysis of comparative studies.
    BJU Int. 2019;123:210-219.
    PubMed     Abstract available


    January 2019
  32. TAN WS, Teo CH, Chan D, Heinrich M, et al
    Mix methods approach to explore patients' perspectives on the acceptability of a urinary biomarker test in replacement of cystoscopy in bladder cancer surveillance.
    BJU Int. 2019 Jan 29. doi: 10.1111/bju.14690.
    PubMed     Abstract available


  33. BAJIC P, Wolfe AJ, Gupta GN
    Old Instillations and New Implications in Bladder Cancer: The Urinary Microbiome and Intravesical BCG.
    BJU Int. 2019 Jan 21. doi: 10.1111/bju.14683.
    PubMed     Abstract available


  34. D'ANDREA D, Soria F, Zehetmayer S, Gust KM, et al
    Diagnostic accuracy, clinical utility and influence on decision making of a methylation urine biomarker test in the surveillance of non-muscle-invasive bladder cancer.
    BJU Int. 2019 Jan 17. doi: 10.1111/bju.14673.
    PubMed     Abstract available


  35. BOERI L, Soligo M, Frank I, Boorjian SA, et al
    Cigarette smoking is associated with adverse pathological response and increased disease recurrence amongst patients with muscle-invasive bladder cancer treated with cisplatin-based neoadjuvant chemotherapy and radical cystectomy: a single-centre expe
    BJU Int. 2019 Jan 8. doi: 10.1111/bju.14612.
    PubMed     Abstract available


  36. TAN WS, Sarpong R, Khetrapal P, Rodney S, et al
    Does urinary cytology have a role in haematuria investigations?
    BJU Int. 2019;123:74-81.
    PubMed     Abstract available


    December 2018
  37. MUNARI E, Calio A, Brunelli M, Martignoni G, et al
    Predicting progression in T1 non-muscle-invasive bladder cancer: back to histology.
    BJU Int. 2018;122:914-915.
    PubMed    


    October 2018
  38. QU LG, Lawrentschuk N
    Bladder cancer surveillance in patients with spinal cord injuries.
    BJU Int. 2018 Oct 8. doi: 10.1111/bju.14582.
    PubMed     Abstract available


  39. SOLOWAY MS
    Postoperative intravesical chemotherapy has an important role in reducing subsequent bladder tumours - why is it not routine?
    BJU Int. 2018;122:525-526.
    PubMed    


    September 2018
  40. SUAREZ-IBARROLA R, Soria F, Abufaraj M, D'Andrea D, et al
    Surgical checklist impact on recurrence-free survival of non-muscle invasive bladder cancer patients undergoing transurethral resection of bladder tumor.
    BJU Int. 2018 Sep 24. doi: 10.1111/bju.14557.
    PubMed     Abstract available


    August 2018
  41. LANE G, Risk M, Fan Y, Krishna S, et al
    Persistent muscle invasive bladder cancer after neoadjuvant chemotherapy: An analysis of SEER-Medicare data.
    BJU Int. 2018 Aug 20. doi: 10.1111/bju.14529.
    PubMed     Abstract available


  42. BREYER J, Wirtz RM, Erben P, Rinaldetti S, et al
    FOXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancer (NMIBC).
    BJU Int. 2018 Aug 18. doi: 10.1111/bju.14525.
    PubMed     Abstract available


  43. HEIJNSDIJK EAM, Nieboer D, Garg T, Lansdorp-Vogelaar I, et al
    Cost-effectiveness of surveillance schedules in older adults with non-muscle-invasive bladder cancer.
    BJU Int. 2018 Aug 1. doi: 10.1111/bju.14502.
    PubMed     Abstract available


  44. GROSS T, Furrer M, Schorno P, Wuethrich PY, et al
    Reproductive organ-sparing cystectomy significantly improves continence in women after orthotopic bladder substitution without affecting oncological outcome.
    BJU Int. 2018;122:227-235.
    PubMed     Abstract available


    July 2018
  45. SMITH A, Daneshmand S, Patel S, Pohar K, et al
    Patient-reported Outcomes of Blue Light Flexible Cystoscopy with Hexaminolevulinate (HAL) in the Surveillance of Bladder Cancer: Results from a Prospective Multi-center Study.
    BJU Int. 2018 Jul 6. doi: 10.1111/bju.14481.
    PubMed     Abstract available


  46. MMEJE CO, Benson CR, Nogueras-Gonzalez GM, Jayaratna IS, et al
    Determining the optimal time for radical cystectomy after neoadjuvant chemotherapy.
    BJU Int. 2018;122:89-98.
    PubMed     Abstract available


    June 2018
  47. JEFFERIES ER, Cresswell J, McGrath JS, Miller C, et al
    Open radical cystectomy in England: the current standard of care - an analysis of the British Association of Urological Surgeons (BAUS) cystectomy audit and Hospital Episodes Statistics (HES) data.
    BJU Int. 2018;121:880-885.
    PubMed     Abstract available


    May 2018
  48. MARI A, Kimura S, Foerster B, Abufaraj M, et al
    A Systematic Review and Meta-Analysis of the impact of Lymphovascular Invasion in Bladder Cancer Transurethral Resection Specimens.
    BJU Int. 2018 May 28. doi: 10.1111/bju.14417.
    PubMed     Abstract available


  49. EREDICS K, Bretterbauer KM, Comploj E, Friedl A, et al
    Bladder cancer in nonagenarians:a multicenter study of 123 patients.
    BJU Int. 2018 May 27. doi: 10.1111/bju.14419.
    PubMed     Abstract available


  50. NA R, Wu Y, Jiang G, Yu H, et al
    Germline Mutations in DNA Repair Genes are Associated with Bladder Cancer Risk and Unfavorable Prognosis.
    BJU Int. 2018 May 4. doi: 10.1111/bju.14370.
    PubMed     Abstract available


  51. GANDHI N, Krishna S, Booth CM, Breau RH, et al
    Diagnostic accuracy of MRI for tumor staging of bladder cancer: Systematic review and Meta-Analysis.
    BJU Int. 2018 May 4. doi: 10.1111/bju.14366.
    PubMed     Abstract available


  52. MASON SJ, Catto JW, Downing A, Bottomley SE, et al
    Evaluating Patient Reported Outcome Measures (PROMs) for bladder cancer: a systematic review using the COSMIN checklist.
    BJU Int. 2018 May 3. doi: 10.1111/bju.14368.
    PubMed     Abstract available


  53. BRASSETTI A, Moller A, Laurin O, Hoijer J, et al
    Evolution of cystectomy care over an 11-year period in a high-volume tertiary referral centre.
    BJU Int. 2018;121:752-757.
    PubMed     Abstract available


    April 2018
  54. FRANSEN VAN DE PUTTE EE, Bosschieter J, van der Kwast TH, Bertz S, et al
    The WHO 1973 classification system for grade is an Important prognosticator in T1 non-muscle-invasive bladder cancer.
    BJU Int. 2018 Apr 10. doi: 10.1111/bju.14238.
    PubMed     Abstract available


  55. CHA EK, Sfakianos JP, Sukhu R, Yee AM, et al
    Poor prognosis of bladder cancer patients with occult lymph node metastases treated with neoadjuvant chemotherapy.
    BJU Int. 2018 Apr 7. doi: 10.1111/bju.14242.
    PubMed     Abstract available


  56. MOSSANEN M, Brown JC, Schrag D
    Well-being beyond the bladder. How do we improve the overall health of patients with bladder cancer?
    BJU Int. 2018;121:489-491.
    PubMed    


  57. GOFRIT ON, Pode D, Pizov G, Duvdevani M, et al
    'Very-low-risk' bladder tumours - a new entity?
    BJU Int. 2018;121:627-631.
    PubMed     Abstract available


  58. TAN WS, Tan MY, Lamb BW, Sridhar A, et al
    Intracorporeal robot-assisted radical cystectomy, together with an enhanced recovery programme, improves postoperative outcomes by aggregating marginal gains.
    BJU Int. 2018;121:632-639.
    PubMed     Abstract available


    March 2018
  59. LOTAN Y, Woldu SL, Sanli O, Black P, et al
    Modeling Cost-Effectiveness of a Biomarker-Based Approach to Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer.
    BJU Int. 2018 Mar 31. doi: 10.1111/bju.14220.
    PubMed     Abstract available


  60. MOSSANEN M, Krasnow RE, Lipsitz SR, Preston MA, et al
    Associations of specific postoperative complications with costs after radical cystectomy.
    BJU Int. 2018;121:428-436.
    PubMed     Abstract available


    February 2018
  61. SEISEN T
    Examining the role of centralisation of radical cystectomy for bladder cancer.
    BJU Int. 2018;121:165-167.
    PubMed    


  62. MINERVINI A, Vanacore D, Vittori G, Milanesi M, et al
    Florence robotic intracorporeal neobladder (FloRIN): a new reconfiguration strategy developed following the IDEAL guidelines.
    BJU Int. 2018;121:313-317.
    PubMed     Abstract available


  63. PERERA M, Papa N, Christidis D, McGrath S, et al
    The impact of the global bacille Calmette-Guerin shortage on treatment patterns: population-based data.
    BJU Int. 2018;121:169-172.
    PubMed    


  64. GUO RQ, Hong P, Xiong GY, Zhang L, et al
    Impact of ureteroscopy before radical nephroureterectomy for upper tract urothelial carcinomas on oncological outcomes: a meta-analysis.
    BJU Int. 2018;121:184-193.
    PubMed     Abstract available


    January 2018
  65. BOSSCHIETER J, van Moorselaar RJA, Vis AN, van Ginkel T, et al
    The Effect of Timing of an Immediate Instillation with Mitomycin C after Transurethral Resection in 941 Non Muscle-invasive Bladder Cancer Patients.
    BJU Int. 2018 Jan 10. doi: 10.1111/bju.14124.
    PubMed     Abstract available


  66. SU J, Zhu Q, Yuan L, Zhang Y, et al
    Transumbilical laparoendoscopic single-site radical prostatectomy and cystectomy with the aid of a transurethral port: a feasibility study.
    BJU Int. 2018;121:111-118.
    PubMed     Abstract available


    December 2017
  67. MIYAKE M, Tatsumi Y, Matsumoto H, Nagao K, et al
    Outcomes of subsequent non-muscle invasive bladder cancer treated with intravesical Bacillus Calmette-Guerin after radical nephroureterectomy for upper urinary tract urothelial carcinoma: A propensity matched analysis with primary bladder cancer.
    BJU Int. 2017 Dec 27. doi: 10.1111/bju.14111.
    PubMed     Abstract available


  68. RITCH CR, Balise R, Soodana Prakash N, Alonzo D, et al
    Propensity matched comparative analysis of survival following chemoradiation or radical cystectomy for muscle invasive bladder cancer.
    BJU Int. 2017 Dec 27. doi: 10.1111/bju.14109.
    PubMed     Abstract available



  69. Bladder cancer: diagnosis and management of bladder cancer: (c) NICE (2015) Bladder cancer: diagnosis and management of bladder cancer.
    BJU Int. 2017;120:755-765.
    PubMed    


  70. MAURICE MJ, Kaouk JH
    Robotic radical perineal cystectomy and extended pelvic lymphadenectomy: initial investigation using a purpose-built single-port robotic system.
    BJU Int. 2017;120:881-884.
    PubMed     Abstract available


  71. DASGUPTA P
    NICE guidance and the BJUI.
    BJU Int. 2017;120:743.
    PubMed    


  72. VAN HEMELRIJCK M
    Human development and its impact on genitourinary cancers.
    BJU Int. 2017;120:747-748.
    PubMed    


    November 2017
  73. AHMADI N, Clifford TG, Miranda G, Cai J, et al
    Impact of body mass index on robot-assisted radical cystectomy with intracorporeal urinary diversion.
    BJU Int. 2017;120:689-694.
    PubMed     Abstract available


  74. HUDDART RA, Birtle A, Maynard L, Beresford M, et al
    Clinical and patient-reported outcomes of SPARE - a randomised feasibility study of selective bladder preservation versus radical cystectomy.
    BJU Int. 2017;120:639-650.
    PubMed     Abstract available


  75. KINNEAR N, Smith R, Hennessey DB, Bolton D, et al
    Implementation rates of uro-oncology multidisciplinary meeting decisions.
    BJU Int. 2017;120 Suppl 3:15-20.
    PubMed     Abstract available


  76. STRATTON K
    Cystectomy for cT4 prostate cancer: the most radical treatment.
    BJU Int. 2017;120.
    PubMed    


    October 2017
  77. XIA L, Taylor BL, Newton AD, Malhotra A, et al
    Early Discharge and Post-Discharge Outcomes in Patients Undergoing Radical Cystectomy for Bladder Cancer.
    BJU Int. 2017 Oct 24. doi: 10.1111/bju.14058.
    PubMed     Abstract available


  78. SMITH AB, Jaeger B, Pinheiro LC, Edwards LJ, et al
    The impact of bladder cancer on health-related quality of life.
    BJU Int. 2017 Oct 8. doi: 10.1111/bju.14047.
    PubMed     Abstract available


  79. LIEDBERG F, Gudjonsson S, Xu A, Bendahl PO, et al
    Long-term third-party assessment of results after continent cutaneous diversion with Lundiana pouch.
    BJU Int. 2017;120:530-536.
    PubMed     Abstract available


    September 2017
  80. PICHLER R, Fritz J, Tulchiner G, Klinglmair G, et al
    Increased Accuracy of a novel mRNA-based Urine Test for Bladder Cancer Surveillance.
    BJU Int. 2017 Sep 20. doi: 10.1111/bju.14019.
    PubMed     Abstract available


  81. VETTERLEIN MW, Gild P, Kluth LA, Seisen T, et al
    Perioperative Allogeneic Blood Transfusion Does Not Adversely Impact Oncological Outcomes After Radical Cystectomy for Urinary Bladder Cancer - a Propensity Score-weighted European Multicenter Study.
    BJU Int. 2017 Sep 14. doi: 10.1111/bju.14012.
    PubMed     Abstract available


  82. LI R, Metcalfe MJ, Ferguson Rd JE, Mokkapati S, et al
    Effects of Thiazolidinedione in Patients with Active Bladder Cancer.
    BJU Int. 2017 Sep 5. doi: 10.1111/bju.14009.
    PubMed     Abstract available


  83. DUDDERIDGE T
    Positive messages for bladder cancer management in negative sentinel lymph node study.
    BJU Int. 2017;120:302-303.
    PubMed    


  84. MARCHIONI M, Primiceri G, Cindolo L, Hampton LJ, et al
    Impact of diagnostic ureteroscopy on intravesical recurrence in patients undergoing radical nephroureterectomy for upper tract urothelial cancer: a systematic review and meta-analysis.
    BJU Int. 2017;120:313-319.
    PubMed     Abstract available


  85. BLUTE ML JR, Kucherov V, Rushmer TJ, Damodaran S, et al
    Reduced estimated glomerular filtration rate (eGFR <60 mL/min/1.73 m2 ) at first transurethral resection of bladder tumour is a significant predictor of subsequent recurrence and progression.
    BJU Int. 2017;120:387-393.
    PubMed     Abstract available


  86. CHAPPIDI MR, Kates M, Tosoian JJ, Johnson MH, et al
    Evaluation of gender-based disparities in time from initial haematuria presentation to upper tract urothelial carcinoma diagnosis: analysis of a nationwide insurance claims database.
    BJU Int. 2017;120:377-386.
    PubMed     Abstract available


    August 2017
  87. WAINGANKAR N, Mallin K, Smaldone M, Egleston BL, et al
    Assessing the relative influence of hospital and surgeon volume on short-term mortality after radical cystectomy.
    BJU Int. 2017;120:239-245.
    PubMed     Abstract available


  88. MILLER C, Campain NJ, Dbeis R, Daugherty M, et al
    Introduction of robot-assisted radical cystectomy within an established enhanced recovery programme.
    BJU Int. 2017;120:265-272.
    PubMed     Abstract available


  89. CATTO JWF
    Speeding up recovery from radical cystectomy: how low can we go?
    BJU Int. 2017;120:162-163.
    PubMed    


    June 2017
  90. MCCOMBIE SP, Bangash HK, Kuan M, Thyer I, et al
    Delays in the diagnosis and initial treatment of bladder cancer in Western Australia.
    BJU Int. 2017 Jun 29. doi: 10.1111/bju.13939.
    PubMed     Abstract available


  91. AFSHAR M, Goodfellow H, Jackson-Spence F, Evison F, et al
    Centralisation of radical cystectomies for bladder cancer in England, a decade on from the 'Improving Outcomes Guidance': The case for super centralisation.
    BJU Int. 2017 Jun 8. doi: 10.1111/bju.13929.
    PubMed     Abstract available


  92. SOAVE A, Riethdorf S, Dahlem R, Minner S, et al
    Detection and oncological effect of circulating tumour cells in patients with variant urothelial carcinoma histology treated with radical cystectomy.
    BJU Int. 2017;119:854-861.
    PubMed     Abstract available


  93. KOCH MO
    Detection and oncological effect of circulating tumour cells in patients with variant urothelial carcinoma histology treated with radical cystectomy.
    BJU Int. 2017;119:816.
    PubMed    


    May 2017
  94. NGO B, Papa N, Perera M, Bolton D, et al
    Bladder cancer diagnosis during haematuria investigation - implications for practice guidelines.
    BJU Int. 2017;119 Suppl 5:53-54.
    PubMed    


  95. HAYNE D
    Bladder cancer - Old lessons yet to be learned.
    BJU Int. 2017;119 Suppl 5:7.
    PubMed    


  96. NGO B, Perera M, Papa N, Bolton D, et al
    Factors affecting the timeliness and adequacy of haematuria assessment in bladder cancer: a systematic review.
    BJU Int. 2017;119 Suppl 5:10-18.
    PubMed     Abstract available


  97. LAWRENTSCHUK N
    Bladder cancer- time for a higher profile in our region.
    BJU Int. 2017;119 Suppl 5:5.
    PubMed    


  98. NGO B, Papa N, Perera M, Bolton D, et al
    Predictors of delay to cystoscopy and adequacy of investigations in patients with haematuria.
    BJU Int. 2017;119 Suppl 5:19-25.
    PubMed     Abstract available


  99. VON LANDENBERG N, Speed JM, Trinh QD
    Do micropapillary patients benefit from chemotherapy?
    BJU Int. 2017;119:656-658.
    PubMed    


  100. DAVIS JW
    Biomarker classification, validation, and what to look for in 2017 and beyond.
    BJU Int. 2017;119:812-814.
    PubMed    


    April 2017
  101. HAYNE D, Stockler M, McCombie SP, Lawrence N, et al
    The BCG + Mitomycin trial for high risk non-muscle-invasive bladder cancer: Progress report and lessons learned.
    BJU Int. 2017 Apr 9. doi: 10.1111/bju.13873.
    PubMed     Abstract available


  102. BAILEY GC, Boorjian SA, Ziegelmann MJ, Westerman ME, et al
    Urinary collecting system invasion is associated with poor survival in patients with clear-cell renal cell carcinoma.
    BJU Int. 2017;119:585-590.
    PubMed     Abstract available


  103. HINATA N, Hussein AA, George S, Trump DL, et al
    Impact of suboptimal neoadjuvant chemotherapy on peri-operative outcomes and survival after robot-assisted radical cystectomy: a multicentre multinational study.
    BJU Int. 2017;119:605-611.
    PubMed     Abstract available


    February 2017
  104. VESKIMAE E, Neuzillet Y, Rouanne M, MacLennan S, et al
    Systematic review of the oncological and functional outcomes of pelvic organ-preserving cystectomy compared with standard radical cystectomy in women who undergo curative surgery and orthotopic neobladder substitution for bladder cancer.
    BJU Int. 2017 Feb 20. doi: 10.1111/bju.13819.
    PubMed     Abstract available


  105. SPAHN M, Morlacco A, Boxler S, Joniau S, et al
    Outcome predictors of radical cystectomy in patients with cT4 prostate cancer: A multi-institutional study of 62 patients.
    BJU Int. 2017 Feb 20. doi: 10.1111/bju.13818.
    PubMed     Abstract available


    January 2017
  106. WOLDU SL, Bagrodia A, Lotan Y
    Guideline of Guidelines - Non-Muscle Invasive Bladder Cancer.
    BJU Int. 2017 Jan 6. doi: 10.1111/bju.13760.
    PubMed     Abstract available


  107. GOLOMBOS DM, O'Malley P, Lewicki P, Stone BV, et al
    Robot-assisted partial cystectomy: perioperative outcomes and early oncological efficacy.
    BJU Int. 2017;119:128-134.
    PubMed     Abstract available


  108. THALMANN GN
    Quality improvement in cystectomy care with enhanced recovery (QUICCER) study.
    BJU Int. 2017;119:4-5.
    PubMed    


    December 2016
  109. HUSSEIN AA, Hinata N, Dibaj S, May PR, et al
    Development, Validation and Clinical Application of Pelvic Lymphadenectomy Assessment and Completion Evaluation (PLACE): Intraoperative Assessment of Lymph Node Dissection after Robot-Assisted Radical Cystectomy for Bladder Cancer.
    BJU Int. 2016 Dec 17. doi: 10.1111/bju.13748.
    PubMed     Abstract available


    October 2016
  110. ALJABERY F, Shabo I, Olson H, Gimm O, et al
    Radio-guided sentinel lymph node detection and lymph node mapping in invasive urinary bladder cancer-a prospective clinical study.
    BJU Int. 2016 Oct 31. doi: 10.1111/bju.13700.
    PubMed     Abstract available


  111. FERNANDEZ MI, Williams SB, Willis DL, Slack RS, et al
    Clinical Risk Stratification in Patients with Surgically Resectable Micropapillary Bladder Cancer.
    BJU Int. 2016 Oct 18. doi: 10.1111/bju.13689.
    PubMed     Abstract available


  112. MATARAZA JM, Gotwals P
    Recent advances in immuno-oncology and its application to urological cancers.
    BJU Int. 2016;118:506-14.
    PubMed     Abstract available


  113. LONGO N, Imbimbo C, Fusco F, Ficarra V, et al
    Complications and quality of life in elderly patients with several comorbidities undergoing cutaneous ureterostomy with single stoma or ileal conduit after radical cystectomy.
    BJU Int. 2016;118:521-6.
    PubMed     Abstract available


  114. ZHANG C, Ma X, Du J, Yao Z, et al
    MicroRNA-30a as a prognostic factor in urothelial carcinoma of bladder inhibits cellular malignancy by antagonising Notch1.
    BJU Int. 2016;118:578-89.
    PubMed     Abstract available


    June 2016
  115. MEYER CP, Rios Diaz AJ, Dalela D, Hanske J, et al
    Wound dehiscence in a sample of 1 776 cystectomies: identification of predictors and implications for outcomes.
    BJU Int. 2016;117.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: